MedTrace Logo

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-06-15

No results posted yet for this study

Summary

This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.

Conditions

  • Childhood Cancer
  • Multiple Diseases

Interventions

BIOLOGICAL

Immunization Schedule patients <7 years.

* Time 0 months: Prevnar 13 #1, Hib #1 * Time 1 months: Pediarix #1 * Time 2 months: Prevnar 13 #2, Hib #2 * Time 3-4 months: Pediarix #2 * Time 4-6 months: Draw post vaccine titers * Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.

BIOLOGICAL

Immunization Schedule patients > or = to 7 years and <11 years of age

* Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1 * Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2 * Time 2-3 months: Prevnar 13 #2, Hib #2 * Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.

BIOLOGICAL

Immunization Schedule patients > or = to 11 years of age

* Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1 * Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2 * Time 2-3 months: Hib #2, Prevnar 13#2, Menactra * Time 3-6 months: IPV, Draw post vaccine titers * Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)

Sponsors & Collaborators

Principal Investigators

  • Nancy Kernan, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-10
Primary Completion
2025-06-11
Completion
2025-06-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505063 on ClinicalTrials.gov